Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Apr;57(4):401–403. doi: 10.1136/jnnp.57.4.401

Drug treatment of Parkinson's disease: is "polypharmacy" best?

P D Swanson 1
PMCID: PMC1072864  PMID: 8163984

Full text

PDF
401

Images in this article

403Image
on p.403

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baronti F., Davis T. L., Boldry R. C., Mouradian M. M., Chase T. N. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology. 1992 Mar;42(3 Pt 1):541–544. doi: 10.1212/wnl.42.3.541. [DOI] [PubMed] [Google Scholar]
  2. Blin J., Bonnet A. M., Agid Y. Does levodopa aggravate Parkinson's disease? Neurology. 1988 Sep;38(9):1410–1416. doi: 10.1212/wnl.38.9.1410. [DOI] [PubMed] [Google Scholar]
  3. Diamond S. G., Markham C. H., Hoehn M. M., McDowell F. H., Muenter M. D. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol. 1987 Jul;22(1):8–12. doi: 10.1002/ana.410220105. [DOI] [PubMed] [Google Scholar]
  4. Elizan T. S., Moros D. A., Yahr M. D. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months. Arch Neurol. 1991 Jan;48(1):31–34. doi: 10.1001/archneur.1991.00530130039017. [DOI] [PubMed] [Google Scholar]
  5. Elizan T. S., Yahr M. D., Moros D. A., Mendoza M. R., Pang S., Bodian C. A. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients. Arch Neurol. 1989 Dec;46(12):1275–1279. doi: 10.1001/archneur.1989.00520480017012. [DOI] [PubMed] [Google Scholar]
  6. Hooshmand H., Quinn J. C., Houff S. A. Cerebrospinal fluid pressure changes with chemotherapy for intracerebral hemorrhage. Neurology. 1972 Jan;22(1):56–61. doi: 10.1212/wnl.22.1.56. [DOI] [PubMed] [Google Scholar]
  7. Lieberman A. N., Gopinathan G., Hassouri H., Neophytides A., Goldstein M. Should dopamine agonists be given early or late? A review of nine years experience with bromocriptine. Can J Neurol Sci. 1984 Feb;11(1 Suppl):233–237. doi: 10.1017/s0317167100046473. [DOI] [PubMed] [Google Scholar]
  8. Markham C. H., Diamond S. G. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol. 1986 Apr;19(4):365–372. doi: 10.1002/ana.410190410. [DOI] [PubMed] [Google Scholar]
  9. Mizuno Y. Drug therapy of Parkinson's disease. An overview. Eur Neurol. 1992;32 (Suppl 1):3–8. doi: 10.1159/000116864. [DOI] [PubMed] [Google Scholar]
  10. Nakanishi T., Iwata M., Goto I., Kanazawa I., Kowa H., Mannen T., Mizuno Y., Nishitani H., Ogawa N., Takahashi A. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report. Eur Neurol. 1992;32 (Suppl 1):9–22. doi: 10.1159/000116865. [DOI] [PubMed] [Google Scholar]
  11. Nakanishi T., Kanazawa I., Goto I., Iwata M., Kowa H., Mannen T., Mizuno Y., Nishitani H., Ogawa N., Takahashi A. Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Eur Neurol. 1990;30 (Suppl 1):3–8. doi: 10.1159/000117167. [DOI] [PubMed] [Google Scholar]
  12. Nakanishi T., Mizuno Y., Goto I., Iwata M., Kanazawa I., Kowa H., Mannen T., Nishitani H., Ogawa N., Takahashi A. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan. Eur Neurol. 1988;28 (Suppl 1):3–8. [PubMed] [Google Scholar]
  13. Nakanishi T., Mizuno Y., Goto I., Iwata M., Kanazawa I., Kowa H., Mannen T., Nishitani H., Ogawa N., Takahashi A. A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report. Eur Neurol. 1991;31 (Suppl 1):3–16. doi: 10.1159/000116716. [DOI] [PubMed] [Google Scholar]
  14. Perry T. L., Yong V. W., Ito M., Foulks J. G., Wall R. A., Godin D. V., Clavier R. M. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem. 1984 Oct;43(4):990–993. doi: 10.1111/j.1471-4159.1984.tb12834.x. [DOI] [PubMed] [Google Scholar]
  15. Przuntek H., Welzel D., Blümner E., Danielczyk W., Letzel H., Kaiser H. J., Kraus P. H., Riederer P., Schwarzmann D., Wolf H. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol. 1992;43(4):357–363. doi: 10.1007/BF02220609. [DOI] [PubMed] [Google Scholar]
  16. Quinn N., Parkes D., Janota I., Marsden C. D. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord. 1986;1(1):65–68. doi: 10.1002/mds.870010109. [DOI] [PubMed] [Google Scholar]
  17. Reynolds E. H., Shorvon S. D. Monotherapy or polytherapy for epilepsy? Epilepsia. 1981 Feb;22(1):1–10. doi: 10.1111/j.1528-1157.1981.tb04327.x. [DOI] [PubMed] [Google Scholar]
  18. Rinne U. K. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology. 1985 Aug;35(8):1196–1198. doi: 10.1212/wnl.35.8.1196. [DOI] [PubMed] [Google Scholar]
  19. Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology. 1987 May;37(5):826–828. doi: 10.1212/wnl.37.5.826. [DOI] [PubMed] [Google Scholar]
  20. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia. 1983 Jun;24(3):368–376. doi: 10.1111/j.1528-1157.1983.tb04900.x. [DOI] [PubMed] [Google Scholar]
  21. Schulzer M., Mak E., Calne D. B. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol. 1992 Dec;32(6):795–798. doi: 10.1002/ana.410320614. [DOI] [PubMed] [Google Scholar]
  22. Tetrud J. W., Langston J. W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989 Aug 4;245(4917):519–522. doi: 10.1126/science.2502843. [DOI] [PubMed] [Google Scholar]
  23. Weiner W. J., Factor S. A., Sanchez-Ramos J. R., Singer C., Sheldon C., Cornelius L., Ingenito A. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology. 1993 Jan;43(1):21–27. doi: 10.1212/wnl.43.1_part_1.21. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES